JP2024519031A - コンジュゲート療法エンハンサーを含む組成物 - Google Patents

コンジュゲート療法エンハンサーを含む組成物 Download PDF

Info

Publication number
JP2024519031A
JP2024519031A JP2023571272A JP2023571272A JP2024519031A JP 2024519031 A JP2024519031 A JP 2024519031A JP 2023571272 A JP2023571272 A JP 2023571272A JP 2023571272 A JP2023571272 A JP 2023571272A JP 2024519031 A JP2024519031 A JP 2024519031A
Authority
JP
Japan
Prior art keywords
moiety
group
composition
independently
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023571272A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024519031A5 (enExample
Inventor
カズミエルスキ，ヴィエスワフ
プラシット，リチャード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biohaven Therapeutics Ltd
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of JP2024519031A publication Critical patent/JP2024519031A/ja
Publication of JP2024519031A5 publication Critical patent/JP2024519031A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023571272A 2021-05-17 2022-05-17 コンジュゲート療法エンハンサーを含む組成物 Pending JP2024519031A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163189503P 2021-05-17 2021-05-17
US63/189,503 2021-05-17
PCT/US2022/029533 WO2022245757A1 (en) 2021-05-17 2022-05-17 Compositions including conjugated therapy enhancers

Publications (2)

Publication Number Publication Date
JP2024519031A true JP2024519031A (ja) 2024-05-08
JP2024519031A5 JP2024519031A5 (enExample) 2025-05-23

Family

ID=84140038

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023571272A Pending JP2024519031A (ja) 2021-05-17 2022-05-17 コンジュゲート療法エンハンサーを含む組成物

Country Status (12)

Country Link
US (1) US20240238436A1 (enExample)
EP (1) EP4351658A4 (enExample)
JP (1) JP2024519031A (enExample)
KR (1) KR20240012376A (enExample)
CN (1) CN117295527A (enExample)
AU (1) AU2022277840A1 (enExample)
BR (1) BR112023023506A2 (enExample)
CA (1) CA3219475A1 (enExample)
IL (1) IL307746A (enExample)
MX (1) MX2023013274A (enExample)
PH (1) PH12023553152A1 (enExample)
WO (1) WO2022245757A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026150353A2 (en) 2025-01-11 2026-07-16 Biohaven Therapeutics Ltd. Antibody-drug conjugates for delivering cytotoxic agents

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019518017A (ja) * 2016-02-09 2019-06-27 アレクサンダー・クランツ トレースレス親和性標識を使用したタンパク質の部位選択的官能化
WO2020153774A1 (ko) * 2019-01-23 2020-07-30 앱티스 주식회사 항체-페이로드 컨쥬게이트 제조용 화합물, 이의 용도
WO2020184944A1 (ko) * 2019-03-08 2020-09-17 앱티스 주식회사 위치특이적 항체 콘쥬게이션 및 이의 구체예로서의 항체-약물 콘쥬게이트
JP2020528937A (ja) * 2017-07-26 2020-10-01 クレオ ファーマシューティカルズ， インコーポレイテッド 普遍的なａｂｔ化合物及びその使用
WO2021102052A1 (en) * 2019-11-18 2021-05-27 Kleo Pharmaceuticals, Inc. Directed conjugation technologies
WO2021110860A1 (en) * 2019-12-03 2021-06-10 Debiopharm Research & Manufacturing S.A. Reactive conjugates
WO2022080385A1 (ja) * 2020-10-13 2022-04-21 国立大学法人京都大学 ペプチド、およびペプチドを用いる抗体の修飾
WO2022079031A1 (en) * 2020-10-12 2022-04-21 Debiopharm Research & Manufacturing S.A. Reactive conjugates

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3134610A1 (en) * 2018-04-09 2019-10-17 Yale University Bifunctional small molecules to target the selective degradation of circulating proteins
WO2019241609A1 (en) * 2018-06-15 2019-12-19 Trustees Of Boston University Polypeptide compositions and methods for site-specific targeting of therapeutic agents
WO2022192478A1 (en) * 2021-03-10 2022-09-15 Biohaven Therapeutics Ltd. Bifunctional degraders of galactose-deficient immunoglobulins
IL307799A (en) * 2021-05-17 2023-12-01 Biohaven Therapeutics Ltd Agents for targeted coupling techniques and conjugated products
EP4340859A4 (en) * 2021-05-19 2025-07-02 Biohaven Therapeutics Ltd ANTIBODY-DRUG CONJUGATES USING COUPLING TECHNOLOGY TO DELIVER CYTOTOXIC AGENTS
WO2023043861A2 (en) * 2021-09-16 2023-03-23 Biohaven Therapeutics Ltd. Conjugated antibodies for treating diseases

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019518017A (ja) * 2016-02-09 2019-06-27 アレクサンダー・クランツ トレースレス親和性標識を使用したタンパク質の部位選択的官能化
JP2020528937A (ja) * 2017-07-26 2020-10-01 クレオ ファーマシューティカルズ， インコーポレイテッド 普遍的なａｂｔ化合物及びその使用
WO2020153774A1 (ko) * 2019-01-23 2020-07-30 앱티스 주식회사 항체-페이로드 컨쥬게이트 제조용 화합물, 이의 용도
WO2020184944A1 (ko) * 2019-03-08 2020-09-17 앱티스 주식회사 위치특이적 항체 콘쥬게이션 및 이의 구체예로서의 항체-약물 콘쥬게이트
WO2021102052A1 (en) * 2019-11-18 2021-05-27 Kleo Pharmaceuticals, Inc. Directed conjugation technologies
WO2021110860A1 (en) * 2019-12-03 2021-06-10 Debiopharm Research & Manufacturing S.A. Reactive conjugates
WO2022079031A1 (en) * 2020-10-12 2022-04-21 Debiopharm Research & Manufacturing S.A. Reactive conjugates
WO2022080385A1 (ja) * 2020-10-13 2022-04-21 国立大学法人京都大学 ペプチド、およびペプチドを用いる抗体の修飾

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DRUG DELIVERY SYSTEM, vol. 35, no. 3, JPN6026019344, 2020, pages 191 - 199, ISSN: 0005862457 *
J.AM.CHEM.SOC., vol. 139, JPN6026019343, 2017, pages 14181 - 14191, ISSN: 0005862456 *

Also Published As

Publication number Publication date
AU2022277840A9 (en) 2023-12-14
CN117295527A (zh) 2023-12-26
AU2022277840A1 (en) 2023-11-30
WO2022245757A1 (en) 2022-11-24
EP4351658A4 (en) 2026-04-15
CA3219475A1 (en) 2022-11-24
PH12023553152A1 (en) 2024-03-11
EP4351658A1 (en) 2024-04-17
US20240238436A1 (en) 2024-07-18
MX2023013274A (es) 2023-11-30
KR20240012376A (ko) 2024-01-29
IL307746A (en) 2023-12-01
BR112023023506A2 (pt) 2024-01-30

Similar Documents

Publication Publication Date Title
JP6979980B2 (ja) 操作されたポリペプチドコンジュゲート
RU2737727C2 (ru) Варианты пертузумаба и их аналитическая характеристика
JP6385525B2 (ja) タンパク質−活性剤コンジュゲートおよびこれを調製するための方法
EP3882261A1 (en) Compound comprising substance with affinity for antibody, cleavage site and reactive group, or salt thereof
WO2019018828A1 (en) METHODS OF QUALITATIVE AND / OR QUANTITATIVE ANALYSIS OF ACTIVATABLE ANTIBODY PROPERTIES AND USES THEREOF
JP6949832B2 (ja) タンパク質コンジュゲート
Vartak et al. Cetuximab-based PROteolysis targeting chimera for effectual downregulation of NSCLC with varied EGFR mutations
JP7846624B2 (ja) ペプチド含有リンカーとの部位特異的抗体－薬物コンジュゲート
US20220288208A1 (en) Cetuximab-ir700 conjugate compositions
JP2020524669A (ja) 抗ｇｌｏｂｏ ｈ抗体を含有する抗体−薬物コンジュゲートおよびその使用
EP4626479A1 (en) Compositions and methods for protein internalization
JP2025124732A (ja) 化合物またはその塩、およびそれらにより得られる抗体
US20240238436A1 (en) Compositions including conjugated therapy enhancers
JP2024519814A (ja) 指向性コンジュゲーション技術のための薬剤及びコンジュゲート生成物
KR20130138608A (ko) 위치 특이적 항체-싸이토톡신 결합체 및 이의 용도
CZ2016742A3 (cs) Konjugát monoklonální protilátky nimotuzumab, jeho komplex s radionuklidy, způsoby jejich přípravy a jejich použití
KR20190033103A (ko) 신규한 옥심 유도체 화합물 및 이를 포함한 항체-약물 복합체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250515

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260519